Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Clesrovimab is an extended half-life RSV neutralizing antibody in development for all infants in their first RSV season and ...

(Corrects headline, paragraph 1 and 2 in Oct. 17 story to show the drug reduced medically attended lower respiratory ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing ...

EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a ...

Respiratory Illness season is right around the corner and experts are urging parents to take action to protect their newborns ...

Study explores the clinical manifestations, risk factors, and 90-day mortality outcomes in adults hospitalized with RSV or ...

The company’s monoclonal antibody met primary endpoints in Phase IIb/III trial in infants entering their first respiratory ...

RSV, or Respiratory Syncytial Virus, is a highly contagious virus that frequently spreads among preschool children, ...

Health experts highlight how this highly contagious disease affects vulnerable populations and share insights on prevention ...

In some good news for women battling locally advanced cervical cancer, new research shows that adding six weeks of ...